Alere Receives FDA CLIA Waiver for Alere™ i Influenza A & B Test, page-7

Macrobee,
If you have a look at the device it certainly isn't lateral flow like the tests BBI sell and subsequently what we are targeting. This is a device which would not be portable and has a much bigger unit than the devices we are playing in. Even though the time frames are quite impressive for the device you highlighted, if you were to compare it to troponin for arguments sake, they already have a device which measures this in a hospital, but it is hardly portable and hence not part of the POC market. Hence it can't be easily carried in a hospital and takes up a lot of space in a medical centre, ambulance or even a pharmacy.
The tests BBI are selling are qualitative in nature ( basically yes or no. Think a pregnancy test ) whereas the devices / tests we are potentially to be involved in will hopefully be qualitative and quantitative ( meaning they will tell the user whether the user is pregnant and potentially how far along). This would be a next generation piece of technology and certainly something that doesn't currently exist.

Think of it like a breathalyser. Currently you are tested roadside with a portable/ handheld device then if it is above the legal limit you move to a much bigger machine much more sensitive. We are in the breathalyser space.